Studies showed that high Notch1 expression correlates with poor progression-free survival and worse immunotherapeutic response in recurrent HCC patients, while Notch1 overexpression promotes cancer cell escape by inhibiting CD8<sup>+</sup> T cell activation. Here, CD8A is linked to cancer.